Add like
Add dislike
Add to saved papers

Synthesis of novel benzylidene analogues of betulinic acid as potent cytotoxic agents.

Different benzylidene derivatives (15a-o and 16a-o) of betulinic acid were designed and synthesized in an effort to develop potent anticancer agents. All the synthesized derivatives along with betulinic acid were evaluated for cytotoxicity against a panel of five different human cancer cell lines A-549 (Lung), PC-3 (Prostate), HCT 116 (Colon), MCF-7 (Breast) and MIA PaCa-2 (Pancreatic) using SRB assay. Pharmacological results showed that compounds 15b, 15c, 15i, 15k, 16a-c and 16l were found to have promising cytotoxic profile against various cancer cell lines tested (IC50 1-2 μM). Best results were observed for compound 16c with IC50 values 1.5, 1.6, 1.36, 3.5 and 3.2 μM against A-549, PC-3, HCT 116, MCF-7 and MIA PaCa-2 cell lines, respectively. Mechanistic study of compound 16c revealed that it inhibits the colony formation and restrict the migration in HCT 116 cells in vitro. It also induces growth arrest with characterized morphological changes and loss of mitochondrial membrane potential (MMP) in a concentration dependent manner.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app